CDK4 and neoplasm: Interestingly, preclinical studies showed that CDK4/6 inhibitors could also regulate mitogenic kinase signaling, inducing senescence and promoting anti-tumor immunity [91,92], providing the rationale of combinations with immunotherapy agents.